Cidara Therapeutics, Inc. (20D0.F)
| Previous Close | 10.20 |
| Open | 10.20 |
| Bid | 10.30 x N/A |
| Ask | 10.60 x N/A |
| Day's Range | 10.20 - 10.20 |
| 52 Week Range | 9.20 - 23.00 |
| Volume | |
| Avg. Volume | 13 |
| Market Cap | 72.663M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -22.64 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireCidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two upcoming presentations at IDWeek 2024, to be held October 16–19, 2024 in Los Angeles, CA. The presentations will highlight clinical data on the safety, pharmacokinetics, and prophyl
- GlobeNewswire
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (R
